CClinicalTrials.gg
CompletedNCT06229314Updated Jan 30, 2024

Effect of Inspiratory Muscle Training in Operated Adolescent Idiopathic Scoliosis

An interventional study of Inspiratory muscle training in Scoliosis Idiopathic Adolescent, sponsored by Nuh Naci Yazgan University. Completed at 1 site in Turkey. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Nuh Naci Yazgan University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2023, registered Jan 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Study summary

In adolescent idiopathic scoliosis (AIS), if the appropriate treatment approach is not applied, the patient's general health condition is negatively affected by the deterioration of pulmonary function. Although studies in the literature evaluate individuals with AIS and investigate the effects of exercise training on their functional capacity, no study has been found examining the effectiveness of post-surgical respiratory muscle strength training (IMT). Therefore, this study was designed as a randomized controlled study with the aim of investigating the effectiveness of IMT in the early post-surgical period in individuals with AIS. Participants included individuals diagnosed with AIS, for whom a surgical decision was made by an orthopedic surgeon, and who could cooperate in the tests to be conducted. Twelve patients were in the IMT group, and 12 were in the sham group. Pulmonary function and respiratory and peripheral muscle strength were measured. Functional capacities were assessed using the Six-Minute Walk Test (6MWT). Disease-specific quality of life (QoL) was evaluated through the Scoliosis Research Society-22 (SRS-22) and Oswestry Low Back Pain Questionnaire, while dyspnea was assessed using the Modified Medical Research Council (mMRC) scale. In the IMT group, IMT was provided at 60% of the Maximum Inspiratory Pressure (MIP), while in the Sham group, IMT was provided at 5% of MIP.

Read the detailed description

There are very few studies in the literature that have investigated the effects of Inspiratory Muscle Training (IMT) to individuals with scoliosis. In a study conducted by Kim et al. in 2005, individuals with scoliosis and spinal cord injuries were given IMT, and after treatment, a decrease in Cobb angles, a significant increase in lung volumes, and respiratory muscle strengths were observed. In a study by Basbug et al. in 2023, the impact of IMT on pulmonary function and functional capacity in individuals with AIS was investigated. There is no study in the literature on providing IMT after surgery in scoliosis patients. It has been shown that surgical treatment alone in scoliosis patients is insufficient to improve respiratory capacity in the short term. Therefore, in this study, we aimed to investigate the effects of postoperative IMT on pulmonary function, functional capacity, and quality of life in AIS patients.

Methods Trial design

This study was planned as a single-blind, randomized, parallel group clinical trial. Participants did not know which group they were in.

Participants

Patients admitted to Kayseri System Hospital between February 2023 and December 2023 and diagnosed with idiopathic scoliosis were included in the study. Data were collected at Nuh Naci Yazgan University Department of Physiotherapy and Rehabilitation Laboratories. We calculated (G*Power Version 3.1.9.4, Franz Faul, Universitat Kiel, Düsseldorf, Germany) a power of 80% with 0.05 significance, a difference to be detected of 0.84 liter, and a standard deviation of 0.59 liter in FVC value, generating a sample of 10 individuals per group. It was planned to take a total of 24 individuals, 12 individuals in each group, by calculating a minimum 20% drop-out rate. A total of 24 individuals, 12 in the IMT group and 12 in the sham group were included in the study.

The study included voluntary individuals diagnosed with AIS, who had been determined eligible for surgery by an orthopedic specialist, were able to cooperate in the tests, and did not have any orthopedic, cardiac, pulmonary, vestibular or neurological diseases other than scoliosis. Participants who had experienced acute infections within the last 15 days were excluded. The data were collected from February 2023 to December 2023.

Randomization

Twenty-four individuals were randomly selected using the computerized randomization method (www.random.org, Dublin, Ireland) among 29 individuals who met the inclusion criteria and volunteered to participate in the study. Then, two numbers series of 12 randomly prepared numbers with numbers between 1 and 24 were created using the computerized randomization method. Based on randomization, the group consisting of the first number series was accepted as the exercise group and the other as the control group. Afterward, the numbers from 1 to 24 were written on paper and put in 24 sealed envelopes. The patients in the study randomly chose an envelope when they came to their appointment and were included in the group where the number series with the chosen number coincided.

Materials

First, sociodemographic information of all individuals included in the study was obtained, and all questionnaires were conducted. Cobb angle was determined by the orthopedist using radiological imaging methods.

Dyspnea was evaluated using the Modified Medical Research Council (mMRC) dyspnea scale. It is a categorical scale in which individuals choose the most appropriate of the five expressions of dyspnea, between 0-4 points, to define their dyspnea levels.

A spirometer (Cosmed Pony FX Spirometer, Milan, Italy) was used to measure forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, peak expiratory flow rate (PEF), and forced expiratory volume from 25-75% (FEF25-75%), based on the European Respiratory Society/American Thoracic Society (ERS/ATS) criteria. The test was performed in the sitting position. At least three technically acceptable measurements were obtained between the two best-measured FEV1 values, with no more than a 5% difference, and the best FEV1 value was selected for analysis.

Respiratory muscle strength was measured (Cosmed Pony FX Spirometer, Milan, Italy). For the measurement of maximum inspiratory pressure (MIP), maximum expiration was performed on the person, and the respiratory tract was immediately closed with a valve. Then, the person was asked to perform maximum inspiration for 1-3 sec. For maximum expiratory pressure (MEP), a maximal inspiration was performed, and then the person was asked to perform a maximal expiration of 2 sec against the closed airway. At least three technically acceptable maneuvers were performed, with no more than a 5% difference between the two best-measured values.

Peripheral muscle strength was determined by measuring handgrip and quadriceps muscle strength using a digital dynamometer (Jtech Commander Muscle Tester, UT, USA). The mean values of the right and left side measurements were obtained. Then, the average of the measurements of the right and left sides were recorded in Newton (N) using each side.

The functional capacity of individuals was evaluated using the Six-Minute Walk Test (6MWT). Before and after the 6MWT, heart rate, blood pressure, oxygen saturation (SpO2) (Cosmed Spiropalm 6MWT, Rome, Italy), and respiratory frequency were assessed, and fatigue levels during exertion and dyspnea were evaluated using the Modified Borg Scale.

The disease-specific QoL for the cases was assessed using the Scoliosis Research Society-22 (SRS-22) scale. The Turkish version of the scale was used. Additionally, the Oswestry questionnaire was used to assess how much back pain affected daily activities.

Intervention

In this study, the primary outcome measurement was the pulmonary function test, and the secondary outcome measurements were dyspnea, respiratory and peripheral muscle strength, functional capacity and QoL. In the preoperative period, dyspnea, pulmonary function, respiratory and peripheral muscle strength, and QoL were evaluated, respectively. Finally, functional capacity was measured with 6MWT. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery (post-op). Inspiratory Muscle Training (IMT) was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device (Powerbreathe Plus, Warwickshire, England) twice a day with 30x2 breaths. The device was adjusted weekly based on the patient's current MIP value, and training continued at 60% of the MIP value. The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week (post-op sixth week), initial tests and questionnaires were repeated for individuals in both groups.

02

Conditions studied

  • Scoliosis Idiopathic Adolescent

Browse trials for

03

In context

Scoliosis

594 studies on the registry are indexed under Scoliosis; 139 are open to participants now.

This study's enrollment of 24 is below the median of 44 across 344 interventional studies indexed under Scoliosis.

Browse Scoliosis studies →

Lead sponsor

Nuh Naci Yazgan University is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • did not have any orthopedic, cardiac, pulmonary, vestibular or neurological diseases other than scoliosis.

Exclusion criteria

Exclusion Criteria:

  • had experienced acute infections within the last 15 days were excluded
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    IMT Group

    The IMT group received IMT at 60% of the measured MIP value. IMT was administered using the Powerbreathe device (Powerbreathe Plus, Warwickshire, England) twice a day with 30x2 breaths. The device was adjusted weekly based on the patient's current MIP value, and training continued at 60% of the MIP value.

    Device: Inspiratory muscle training

  • Sham comparator
    Control Group

    The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks.

    Device: Inspiratory muscle training

Interventions

  • DeviceInspiratory muscle training

    In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\'s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.

06

What researchers measure

Primary outcomes

  1. Pulmonary function

    A spirometer (Cosmed Pony FX Spirometer, Milan, Italy) was used to measure forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, peak expiratory flow rate (PEF), and forced expiratory volume from 25-75% (FEF25-75%), based on the European Respiratory Society/American Thoracic Society (ERS/ATS) criteria. The test was performed in the sitting position. At least three technically acceptable measurements were obtained between the two best-measured FEV1 values, with no more than a 5% difference, and the best FEV1 value was selected for analysis.

    Time frame: Six week

Secondary outcomes

  1. Dyspnea

    Dyspnea was evaluated using the Modified Medical Research Council (mMRC) dyspnea scale. It is a categorical scale in which individuals choose the most appropriate of the five expressions of dyspnea, between 0-4 points, to define their dyspnea levels

    Time frame: Six week

  2. Respiratory muscle strength

    Evaluated using spirometry device

    Time frame: Six week

  3. Peripheral muscle strength

    Evaluated using digital dynamometer

    Time frame: Six week

  4. Functional capacity

    Six Minute Walk Test is used

    Time frame: Six week

  5. Quality of Health

    Scoliosis Research Society-22 (SRS-22) scale. The scale consists of 22 questions and 5 question subgroups. Subgroups; It consists of pain, evaluation of general appearance, spinal functions, mental health and satisfaction with treatment. The score range of the scale is "0 - 110". Higher scores indicate more severe pain.

    Time frame: Six week

07

Study locations

1 site
  • Nuh Naci Yazgan University
    Kayseri, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06229314
Lead sponsor
Nuh Naci Yazgan University
Responsible party
Ukbe Sirayder (Principal Investigator, Nuh Naci Yazgan University) — Principal investigator
First posted
Jan 29, 2024
Start date
Mar 1, 2023
Primary completion
Jul 15, 2023
Completion
Dec 15, 2023
Last update
Jan 30, 2024

Study contacts

Ukbe ŞIRAYDER, Dr.
principal investigator · Nuh Naci Yazgan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion